Banner Image

Test Directory

JAK2 V617F Mutation Analysis

Order Code: JK2617

Test Summary

This advanced DNA-based, next-generation sequencing (NGS) assay analyses leukocytes from blood or bone marrow aspirate for mutation at condon 617 of JAK2. The JAK2 V617F mutation is associated with myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Aliases

  • Myeloproliferative neoplasm
  • PNF
  • MPN
  • Next-Generation Sequencing Essential Thrombocythemia (ET)
  • NGS
  • Janus Kinase 2
  • Polycythemia Vera (PV)
  • JAK
  • ET
  • Primary Myelofibrosis (PMF)
  • PV

Specimen Collection

Order Code

JK2617

EPIC (Premier) Code

LAB6122

Includes

N/A

CPT Code

  • 81270

Billing Code

  • 671151

CPT Statement

Methodology

Next-Generation Sequencing

FDA Status

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Physician Attestation of Informed Consent

N/A

Testing Laboratory

Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly VA, 20153

Department

Reference Testing

Reference Range

See Laboratory Report

Setup Schedule / Expected Turnaround Time

Daily; Report available: 5 - 7 days

Specimen Collection

Billing

CPT Code

  • 81270

Billing Code

  • 671151

CPT Statement

Result Information

Methodology

Next-Generation Sequencing

Testing Laboratory

N/A

Reference Range

See Laboratory Report

Setup Schedule / Expected Turnaround Time

Daily; Report available: 5 - 7 days